Related Experiment Video
Updated: Sep 30, 2026

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Decoding obstructive sleep apnea phenotypes through integrated multimodal sleep EEG
Junxiao Zheng1, Qinwei Yu2, Yugen Qiu3
1Faculty of Health Sciences, University of Macau, Macau; Centre for Cognitive and Brain Sciences, University of Macau, Macau; Zhuhai UM Science & Technology Research Institute, Guangdong-Macao In-Depth Cooperation Zone in Hengqin, China; School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
Abstract:
Obstructive sleep apnea (OSA) is a heterogeneous disorder poorly characterized by the apnea-hypopnea index (AHI), with current subtyping overlooking sleep neurophysiology. We aimed to identify objective neurophysiological phenotypes and mechanisms by integrating multimodal sleep EEG with clinical and biomarker data. We analyzed polysomnographic, demographic, and biomarker data from 309 OSA patients, extracting quantitative EEG (qEEG) features spanning spectral power and sleep microstructure. These were fused via a cascaded multimodal transformer, and phenotypes identified by consensus clustering. Three stable, clinically distinct phenotypes emerged, with the ten most discriminatory features being all qEEG-derived. Phenotype 0 (n = 52) was the youngest group and showed intermediate sleep architecture, with a numerical trend toward higher self-reported cardiovascular disease; Phenotype 1 (n = 131) exhibited marked N3 sleep deficit and the most aberrant EEG spectral profile; and Phenotype 2 (n = 126) showed preserved sleep architecture. Mean AHI did not differ significantly, yet the distribution of AHI severity categories differed across phenotypes, highlighting a dissociation between conventional severity metrics and neurophysiological subtypes. We introduce a physiology-driven OSA taxonomy decoupled from AHI, prioritizing brain signatures to enable biologically targeted diagnosis and therapy of OSA.

